JSK Venture Capital invests in early-stage companies at the intersection of health, AI and applied frontier technology, backing founders with the ambition to build globally scalable category leaders.
We combine founder experience, disciplined capital and the right network to support companies from early traction to international growth.
€10M internal capital
(Series B only for follow on)
(selectively other geographies, case by case)
Healthtech, medtech, femtech, mental health, agetech and animal health. We back companies improving how care is accessed, delivered, measured and scaled through technology.
Applied AI, deep tech, robotics, quantum applications, climate technologies solving high-value real-world problems.
We are not generalists. We invest selectively in sectors where we have expertise, strong conviction and the ability to create value beyond capital. Outside our core focus, we pursue only exceptional opportunities with a clear strategic fit and a credible path to global scale.
We believe the best venture investments are built on conviction, not volume.
We invest early, stay selective and build concentrated portfolios around exceptional founders solving meaningful problems.
Our role does not end with capital.
We support companies through strategic milestones, fundraising, international expansion and access to the right network.
We work both as lead and co-investors and believe that strong syndicates create stronger companies. We believe long-term partnerships create long-term value.
.svg&w=1200&q=75)
.svg&w=256&q=75){kind=small}
Senior loneliness is a growing challenge. An ageing population and the increasingly busy lives of younger generations can make it harder for families to stay connected. InTouch, founded by Vassili le Moigne, uses artificial intelligence to help address this challenge. The platform connects seniors with their families and helps bridge the gap between technology and human relationships. Our investment in InTouch reflects our focus on technologies that address the needs of an ageing population and have the potential to scale globally.
The digital world brings not only opportunities but also challenges - especially for young people, whose mental health is increasingly threatened by the pressures of social networks and online communication. Elin.ai is a mobile app that acts as a cognitive antivirus, helping young people manage stressful situations and providing support to deal with anxiety, depression or cyberbullying. By investing in this startup, we are pursuing our goal of supporting companies with a positive social impact.
iSono Health is ushering in a new era of preventive women’s healthcare with its fully automated and portable 3D breast ultrasound system, ATUSA™. The project was born from the personal and professional motivation of two inspiring women who, based on their own experiences, developed a technology that enables fast, comfortable, and accurate diagnostics.
VETSTOR is a digital platform for modern veterinary care that connects pet owners, veterinarians and health data in one place. By integrating with veterinary clinics, it gives pet owners access to digital health records, appointment reminders and personalized care recommendations. The platform also helps owners compare and arrange pet health insurance tailored to their pet’s needs, while providing veterinarians with digital tools that streamline everyday care.
Lightly Technologies is a DeepTech company building an AI-powered forensic intelligence platform to combat the fentanyl and opioid crisis. Its Lightly Hub connects chemical identification with AI-powered analysis and real-time intelligence sharing, helping trace substances to their origin and link cases across jurisdictions. To bring these capabilities into the field, Lightly developed Catcher, a portable device that identifies drugs and counterfeit pharmaceuticals in under 10 minutes using patented UV fingerprinting technology.
Surgery saves lives, but access to advanced surgical care remains deeply unequal. A shortage of highly trained surgeons, high procedure costs and variability in outcomes continue to limit access worldwide. Andromeda Surgical is developing a next-generation AI-powered robotic platform for autonomous surgery, designed to make complex minimally invasive procedures more precise, consistent and accessible. The company holds ISO 13485 and MDSAP certifications and is preparing for FDA 510(k) clearance. Andromeda is starting in urology, with the ambition to expand its technology to other surgical procedures over time.
MintNeuro is a UK DeepTech company and Imperial College London spinout developing specialised semiconductor chips for the next generation of neurotechnology. Its modular platform enables neural devices to record, process and stimulate signals from the brain and nervous system, supporting applications such as brain-computer interfaces, neural implants and neuromodulation therapies. By reducing power consumption, device size and development complexity, MintNeuro helps medical technology companies accelerate the development of innovative treatments for neurological and mental health conditions.
Founder, Managing Partner & Chief Investment Officer
Investment Director
Investment Analyst
Healthcare, technology, venture capital and international experts supporting sourcing, validation and growth.
Finance, IT, operations, people, organisation and marketing specialists providing targeted expertise where it can materially support portfolio companies.
An investment in the Sub-Fund involves a high level of risk, limited liquidity and a recommended holding period of 9 years. The Sub-Fund has a summary risk indicator of 6 out of 7. Investors may lose part or all of their investment. The investment is also subject to specific venture capital, concentration, valuation and capital call risks. Full information on risks is available in the relevant KIDs and the Sub-Fund Statute. The investment is also subject to specific venture capital, concentration, valuation, FX and capital call risks.
An investment in the Sub-Fund involves a high level of risk, limited liquidity and a recommended holding period of 9 years. The Sub-Fund has a summary risk indicator of 6 out of 7. Investors may lose part or all of their investment. The investment is also subject to specific venture capital, concentration, valuation and capital call risks. Full information on risks is available in the relevant KIDs and the Sub-Fund Statute. The investment is also subject to specific venture capital, concentration, valuation, FX and capital call risks.
Investiční fond JSK Investments SICAV Simony a Jaromíra Kijonkových se zapojil do investičního kola britské společnosti MintNeuro, v němž firma získala pět milionů dolarů (asi 109 milionů korun) Londýnský spin-off Imperial College London vyvíjí specializované čipy pro neurální zařízení od implantátů po nositelnou elektroniku. Získané prostředky využije k uvedení produktů na trh, rozšíření dodávek předsériových čipů partnerům a posílení své pozice především v USA.
Krátce poté, co se fond JSK Investments podnikatelky Simony Kijonkové zúčastnil Series A kola amerického startupu Andromeda Surgical, oznámil další investici v oblasti zdravotnických technologií. Tentokrát se zapojil do investičního kola britské společnosti MintNeuro, která vyvíjí specializované čipy pro neurotechnologie. Firma v něm získala celkem pět milionů dolarů, tedy zhruba 109 milionů korun.
Investment fund JSK Investments SICAV a.s. has participated in a $5 million funding round for UK-based MintNeuro. The London-based Imperial College London spin-out develops specialised chips for neural devices, from implants to wearable electronics. The company will use the funding to bring its products to market, expand shipments of pre-production chips to partners and strengthen its presence, particularly in the United States.
The Venture Capital Fund is a dedicated early-stage investment strategy within JSK Investments SICAV a.s. It combines the strength of a broader investment platform with an independent investment mandate, dedicated capital allocation, and separate investment governance. Capital is managed independently and is not shared across investment strategies.
JSK Investments SICAV a.s. is a self-managed investment fund within the meaning of Section 8 of Act No. 240/2013 Coll., on Investment Companies and Investment Funds; that is, an investment fund with legal personality that, pursuant to a license issued by the Czech National Bank, is authorized to manage its own assets and exceed the applicable limit.
In Venture Capital, we back ambitious founders building globally scalable companies at the intersection of health, AI and applied frontier technologies. We bring capital, company-building and scaling experience, hands-on support, and access to an international network of experts, entrepreneurs and investors. We build long-term partnerships based on transparency and a shared commitment to creating lasting value.
Československá obchodní banka, a.s.
ALT investiční společnost a.s.
JSK Investments Venture Capital Fund I, podfond - Statute (Czech only)
JSK Investments Venture Capital Fund I, podfond - KID A-EUR (Czech only)
JSK Investments Venture Capital Fund I, podfond - KID B-EUR (Czech only)
JSK Investments Venture Capital Fund I, podfond - Public Offering of Shares (class A, Czech only)
This form is intended solely for requests for general information or a callback. It cannot be used to subscribe for investment shares or to place an investment order. Any subscription process is carried out through the Fund’s Administrator.